Universidad Autonoma de Nuevo León- School of Medicine - Dermatology Department Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico.
Australas J Dermatol. 2020 May;61(2):e234-e237. doi: 10.1111/ajd.13224. Epub 2020 Jan 27.
A leprosy reaction resembling Sweet syndrome was first described in 1987. This cutaneous manifestation can be classified as the type 2 reaction which arises from antigen-antibody interaction. It can occur in patients with diagnosed or undiagnosed leprosy, and men with borderline leprosy tend to exhibit this type of reaction. Triggering factors may include WHO multibacillary treatment or prescription antibiotics. Several reports of this clinical phenomenon have been published, making physicians consider it as part of this spectrum of the disease. Treatment regime can include systemic steroids and thalidomide.
1987 年首次描述了一种类似于Sweet 综合征的麻风反应。这种皮肤表现可分为 2 型反应,由抗原抗体相互作用引起。它可发生在已确诊或未确诊的麻风病患者中,边缘型麻风病男性患者容易出现这种类型的反应。触发因素可能包括世界卫生组织多菌型治疗或处方抗生素。已经发表了几篇关于这种临床现象的报告,使医生认为它是该病谱的一部分。治疗方案可包括全身类固醇和沙利度胺。